Introduction
Pulmonary Arterial Hypertension (PAH) is a progressive and life-threatening condition characterized by elevated blood pressure in the pulmonary arteries. This increased resistance forces the right ventricle to work harder, eventually leading to hypertrophy and heart failure. A central player in PAH pathogenesis is the endothelin system. Endothelin-1 (ET-1), a potent vasoconstrictor, promotes the abnormal proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), contributing to the vascular remodeling that defines the disease.
While several Endothelin Receptor Antagonists (ERAs) are currently used in clinical practice, there is a continuous need for novel agents with improved efficacy and safety profiles. Specifically, many existing ERAs are associated with liver toxicity, often linked to the inhibition of the bile salt export pump (BSEP). This study introduces Pipersentan, a novel dual ERA designed to address these challenges with high potency and a superior safety margin.
Methods and Materials
The research followed a comprehensive pharmacological evaluation pipeline, spanning from de novo chemical synthesis to validation in in vivo disease models.
Chemical Synthesis
Pipersentan, chemically identified as 5-(1,3-Benzodioxol-5-yl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(2-methoxyethylsulfamoyl)pyrimidin-4-amine, was synthesized via a three-step de novo route. The process involved nucleophilic substitution of a pyrimidine derivative (M1) with ethylene glycol (M2) to form M3, followed by Suzuki coupling with a boronic ester (M4) to yield M5. The final step involved another nucleophilic substitution with a bromopyrimidine (M6) to produce the final compound.
Pharmacological and Safety Assays
In vitro studies utilized radioligand binding assays in Chinese hamster ovary (CHO) cells overexpressing human $ET_A$ and $ET_B$ receptors. Functional assays were conducted using primary human pulmonary artery smooth muscle cells (hPASMCs) to evaluate the drug's ability to inhibit ET-1-induced calcium mobilization, cell migration, and proliferation. To predict potential liver injury, the inhibitory effect of Pipersentan on BSEP was measured and compared to Macitentan, a leading FDA-approved ERA.
In Vivo Models
The efficacy of Pipersentan was tested in two established rat models:
- Monocrotaline (MCT)-induced PH: A toxin-based model representing severe vascular injury.
- Hypoxia-induced PH: A model simulating chronic low-oxygen environments.
Hemodynamic parameters, including mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP), were measured alongside the Right Ventricular Hypertrophy Index (RVHI).
Results
Receptor Affinity and Selectivity
Pipersentan demonstrated high affinity for the $ET_A$ receptor (IC50 ~1.6 nM) and lower affinity for $ET_B$ (IC50 ~32.0 µM). This dual but $ET_A$-selective profile is advantageous for maximizing vasodilation while preserving $ET_B$-mediated clearance of ET-1.
Cellular and In Vivo Efficacy
In hPASMCs, Pipersentan effectively inhibited ET-1-induced proliferation and migration in a concentration-dependent manner without exhibiting direct cytotoxicity. In both the MCT and hypoxia rat models, oral administration of Pipersentan significantly reduced mPAP and RVSP. Notably, in the MCT model, a 15 mg/kg dose of Pipersentan showed comparable efficacy to a 30 mg/kg dose of Macitentan, suggesting high in vivo potency. Furthermore, Pipersentan treatment effectively mitigated right ventricular hypertrophy, as evidenced by a reduction in RVHI.
Safety Profile
A critical finding was Pipersentan’s significantly lower potential for liver toxicity. Its inhibitory effect on BSEP was 93 times weaker than that of Macitentan. This suggests a substantially wider safety margin for long-term clinical application compared to current gold-standard treatments.
Discussion and Conclusion
Pipersentan emerges as a potent and selective dual endothelin receptor antagonist with significant therapeutic potential for PAH. By effectively reducing pulmonary arterial pressure and reversing cardiac remodeling in preclinical models, it addresses the core pathologies of the disease.
The most compelling advantage of Pipersentan is its favorable safety profile regarding BSEP inhibition, potentially overcoming the hepatotoxicity limitations that hinder current ERAs. While these results in rat models are encouraging, further studies are required to evaluate human pharmacokinetics and long-term safety. Pipersentan represents a significant step forward in the development of safer, more effective treatments for pulmonary hypertension.
Summary updated